Ping Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ping Yang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Guoshuang Shen
Breast Disease Diagnosis and Treatment Center of Qinghai University Affiliated Hospital & Affiliated Cancer Hospital of Qinghai University, Xining, China
3 shared publications - Hengheng Zhang
Qinghai University, Xining, China
3 shared publications - Jinming Li
Qinghai University, Xining, China
3 shared publications - Yi Zhao
The Center of Breast Disease Diagnosis and Treatment of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining 810000, China
3 shared publications - Chengrong Zhang
Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University and Affiliated Cancer Hospital of Qinghai University, Xining, China
2 shared publications - Fuxing Zhao
Breast Disease Diagnosis and Treatment Center of Qinghai University Affiliated Hospital & Affliated Cancer Hospital of Qinghai University, Xining, China
2 shared publications
Latest Publications
- Open Access
- 29 September 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-11
Effect of body mass index on postoperative lymphedema after breast cancer: a systematic review and meta-analysis
Background Upper extremity lymphedema, a major complication post-breast cancer surgery, severely impacts quality of life. While body mass index (BMI) is suggested as a risk factor for postoperative breast cancer-related lymphedema (BCRL), evidence is inconsistent. This meta-analysis systematically evaluates BMI’s impact on postoperative lymphedema to resolve discrepancies and provide accurate insights. Methods The authors conducted comprehensive literature searches from inception to October 7, 2024, in major English-language databases, including PubMed, Embase, and Cochrane. To assess the association between BMI and postoperative BCRL, odds ratio (OR) with 95% confidence intervals (95% CI) were calculated. Subgroup analyses were also performed to evaluate the impact of BMI on postoperative lymphedema in breast cancer patients across different geographic regions. Results This meta-analysis included 16 studies involving 6,057 postoperative breast cancer patients, with sample sizes ranging from 101 to 1,130. The results revealed a significant association between elevated BMI and postoperative BCRL, with an OR of 2.05 (95% CI, 1.53–2.75; P < 0.005) for patients with BMI ≥ 25 kg/m² compared to those with BMI < 25 kg/m². These findings underscore a significant positive correlation between higher BMI and an increased risk of postoperative lymphedema in breast cancer patients. Conclusions Our findings demonstrate that a BMI ≥ 25 kg/m² is a significant risk factor for postoperative lymphedema in breast cancer patients. A comprehensive understanding of BMI’s role in lymphedema development post-surgery can inform clinicians and therapists in designing personalized strategies to mitigate this complication.
- 29 September 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-11
Open AccessEffect of body mass index on postoperative lymphedema after breast cancer: a systematic review and meta-analysis
Background Upper extremity lymphedema, a major complication post-breast cancer surgery, severely impacts quality of life. While body mass index (BMI) is suggested as a risk factor for postoperative breast cancer-related lymphedema (BCRL), evidence is inconsistent. This meta-analysis systematically evaluates BMI’s impact on postoperative lymphedema to resolve discrepancies and provide accurate insights. Methods The authors conducted comprehensive literature searches from inception to October 7, 2024, in major English-language databases, including PubMed, Embase, and Cochrane. To assess the association between BMI and postoperative BCRL, odds ratio (OR) with 95% confidence intervals (95% CI) were calculated. Subgroup analyses were also performed to evaluate the impact of BMI on postoperative lymphedema in breast cancer patients across different geographic regions. Results This meta-analysis included 16 studies involving 6,057 postoperative breast cancer patients, with sample sizes ranging from 101 to 1,130. The results revealed a significant association between elevated BMI and postoperative BCRL, with an OR of 2.05 (95% CI, 1.53–2.75; P < 0.005) for patients with BMI ≥ 25 kg/m² compared to those with BMI < 25 kg/m². These findings underscore a significant positive correlation between higher BMI and an increased risk of postoperative lymphedema in breast cancer patients. Conclusions Our findings demonstrate that a BMI ≥ 25 kg/m² is a significant risk factor for postoperative lymphedema in breast cancer patients. A comprehensive understanding of BMI’s role in lymphedema development post-surgery can inform clinicians and therapists in designing personalized strategies to mitigate this complication.
- 19 August 2025
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 20 (5) , 2593-2605
The efficacy of acupuncture in the treatment of chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis
Purpose Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect in cancer patients, often emerging within the first month of chemotherapy. Severe CIPN can disrupt daily life, necessitating chemotherapy adjustments or discontinuation, which may increase cancer mortality. No standardized treatment exists, but acupuncture is widely used in China for CIPN.This study aimed to comprehensively assess the actual efficacy of acupuncture in treating CIPN in cancer patients. Methods We searched PubMed, Web of Science, Embase, and Cochrane Library up to October 2024 for randomized controlled trials (RCTs) on acupuncture for CIPN, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Methodological quality was assessed using the Cochrane risk-of-bias tool (RoB 2.0) and the modified Jadad scale. A random-effects model was used to analyze the Effect Size (ES) and 95% Confidence Interval (CI).Data analysis was performed using RevMan 5.3 software. Results The final analysis incorporated 1,048 patients from 18 studies. The results presented in the forest plot demonstrated that, when compared to the control group, acupuncture exhibited superior efficacy in improving CIPN symptoms (RR = 1.11, 95%CI [1.01,1.21]), alleviating pain (SMD = -0.93, 95%CI [-1.63,-0.22]), enhancing quality of life (QoL) (MD = − 1.14, 95%CI [− 1.97, − 0.31]), and reducing chemotherapy-related neurotoxicity (MD = − 3.34, 95%CI [− 5.24, − 1.44]). Additionally, in alleviating CIPN-related pain, simple acupuncture demonstrates superior efficacy compared to electroacupuncture. Conclusion This study clearly demonstrates that acupuncture offers more substantial benefits to CIPN patients compared to usual care, medication, vitamin, and sham acupuncture. This research serves as a valuable reference for cancer patients, physicians, nurses, and other professional medical practitioners.
- 19 August 2025
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 20 (5) , 2593-2605
The efficacy of acupuncture in the treatment of chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis
Purpose Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect in cancer patients, often emerging within the first month of chemotherapy. Severe CIPN can disrupt daily life, necessitating chemotherapy adjustments or discontinuation, which may increase cancer mortality. No standardized treatment exists, but acupuncture is widely used in China for CIPN.This study aimed to comprehensively assess the actual efficacy of acupuncture in treating CIPN in cancer patients. Methods We searched PubMed, Web of Science, Embase, and Cochrane Library up to October 2024 for randomized controlled trials (RCTs) on acupuncture for CIPN, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Methodological quality was assessed using the Cochrane risk-of-bias tool (RoB 2.0) and the modified Jadad scale. A random-effects model was used to analyze the Effect Size (ES) and 95% Confidence Interval (CI).Data analysis was performed using RevMan 5.3 software. Results The final analysis incorporated 1,048 patients from 18 studies. The results presented in the forest plot demonstrated that, when compared to the control group, acupuncture exhibited superior efficacy in improving CIPN symptoms (RR = 1.11, 95%CI [1.01,1.21]), alleviating pain (SMD = -0.93, 95%CI [-1.63,-0.22]), enhancing quality of life (QoL) (MD = − 1.14, 95%CI [− 1.97, − 0.31]), and reducing chemotherapy-related neurotoxicity (MD = − 3.34, 95%CI [− 5.24, − 1.44]). Additionally, in alleviating CIPN-related pain, simple acupuncture demonstrates superior efficacy compared to electroacupuncture. Conclusion This study clearly demonstrates that acupuncture offers more substantial benefits to CIPN patients compared to usual care, medication, vitamin, and sham acupuncture. This research serves as a valuable reference for cancer patients, physicians, nurses, and other professional medical practitioners.
- Open Access
- 1 September 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-13
Causality between autoimmune diseases and breast cancer: a two-sample Mendelian randomization study in a European population
Background The incidence of autoimmune diseases and breast cancer is significantly higher in women compared to men. Previous observational studies have not conclusively determined the relationship between these two conditions. This study utilizes the Mendelian randomization approach to investigate the genetic association between autoimmune diseases and breast cancer. Method Two-sample Mendelian randomization was conducted on a European population using the GWAS database. The inverse variance-weighted method served as the primary analytical approach. The MR-PRESSO test was applied to detect horizontal pleiotropy. To ensure result robustness, the FDR correction method was used. Result The study revealed that Sjögren’s syndrome lowers the overall risk of breast cancer (OR 0.96, 95% CI [0.93–0.99], p = 0.011). Idiopathic inflammatory myopathy shows a protective effect against overall breast cancer (OR 0.98, 95% CI [0.97–0.99], p = 0.035). An association was identified between rheumatoid arthritis and overall breast cancer (OR 0.98, 95% CI [0.96–1.00], p = 0.050). No causal link was found between systemic lupus erythematosus, systemic sclerosis, and overall breast cancer. The study also suggests that Sjögren’s syndrome, rheumatoid arthritis, and idiopathic inflammatory myopathy might reduce the risk of developing HER + breast cancer. Specifically, Sjögren’s syndrome (OR = 0.90, 95% CI [0.83–0.98], p = 0.02), rheumatoid arthritis (OR = 0.94, 95% CI [0.91–0.98], p = 0.006), and idiopathic inflammatory myopathy (OR = 0.96, 95% CI [0.93–0.99], p = 0.036). Additionally, systemic lupus erythematosus was found to lower the risk of HER- breast cancer (OR = 0.95, 95% CI [0.91–0.99], p = 0.046). The study did not establish a causal relationship between these five autoimmune diseases and ER + or ER- breast cancer. Conclusion This study found that autoimmune diseases may act as protective factors against breast cancer risk.
- 1 September 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-13
Open AccessCausality between autoimmune diseases and breast cancer: a two-sample Mendelian randomization study in a European population
Background The incidence of autoimmune diseases and breast cancer is significantly higher in women compared to men. Previous observational studies have not conclusively determined the relationship between these two conditions. This study utilizes the Mendelian randomization approach to investigate the genetic association between autoimmune diseases and breast cancer. Method Two-sample Mendelian randomization was conducted on a European population using the GWAS database. The inverse variance-weighted method served as the primary analytical approach. The MR-PRESSO test was applied to detect horizontal pleiotropy. To ensure result robustness, the FDR correction method was used. Result The study revealed that Sjögren’s syndrome lowers the overall risk of breast cancer (OR 0.96, 95% CI [0.93–0.99], p = 0.011). Idiopathic inflammatory myopathy shows a protective effect against overall breast cancer (OR 0.98, 95% CI [0.97–0.99], p = 0.035). An association was identified between rheumatoid arthritis and overall breast cancer (OR 0.98, 95% CI [0.96–1.00], p = 0.050). No causal link was found between systemic lupus erythematosus, systemic sclerosis, and overall breast cancer. The study also suggests that Sjögren’s syndrome, rheumatoid arthritis, and idiopathic inflammatory myopathy might reduce the risk of developing HER + breast cancer. Specifically, Sjögren’s syndrome (OR = 0.90, 95% CI [0.83–0.98], p = 0.02), rheumatoid arthritis (OR = 0.94, 95% CI [0.91–0.98], p = 0.006), and idiopathic inflammatory myopathy (OR = 0.96, 95% CI [0.93–0.99], p = 0.036). Additionally, systemic lupus erythematosus was found to lower the risk of HER- breast cancer (OR = 0.95, 95% CI [0.91–0.99], p = 0.046). The study did not establish a causal relationship between these five autoimmune diseases and ER + or ER- breast cancer. Conclusion This study found that autoimmune diseases may act as protective factors against breast cancer risk.
- 11 April 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 133, 111961
Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis
- 11 April 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 133, 111961
Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis